Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.48 |
| ▸ | SLC26A6 | Q9BXS9 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.48 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL553327 | 0.88 | TSHR (0.50) | SMN1; SMN2KLKB1LMNANR1H2NR1H3 | |
| SCHEMBL28824358 | 0.87 | RNASEH1 (0.56) | KLKB1NR1H2NR1H3RAB9ANPC1 | |
| SCHEMBL23159308 | 0.85 | SMN1; SMN2 (0.39) | SMN1; SMN2KLKB1SLC26A6KDM4ELMNA | |
| SCHEMBL28042800 | 0.84 | NR1H2 (0.49) | KLKB1NR1H2NR1H3RAB9ANPC1 | |
| SCHEMBL24167145 | 0.82 | NR1H2 (0.53) | KLKB1LMNANR1H2NR1H3RAB9A | |
| SCHEMBL19224520 | 0.82 | NR1H2 (0.56) | KLKB1NR1H2NR1H3RAB9ANPC1 | |
| SCHEMBL23085471 | 0.79 | NR1H2 (0.53) | KLKB1NR1H2NR1H3RAB9ANPC1 | |
| SCHEMBL7059235 | 0.78 | ALDH1A1 (0.51) | SMN1; SMN2KDM4ELMNARAB9ANPC1 | |
| SCHEMBL30848602 | 0.78 | NR1H2 (0.51) | KLKB1NR1H2NR1H3RAB9ANPC1 | |
| SCHEMBL2578827 | 0.77 | PDE4D (0.45) | SMN1; SMN2KDM4ELMNARAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4055021-B1 | HETEROCYCLIC RIP1 INHIBITORY COMPOUNDS | RIGEL PHARMACEUTICALS INC (US) | 2025-10-08 | — | — | EP | disclosed |
| CN-112384510-B | RIP1 inhibitory compounds and methods of making and using the same | 里格尔药品股份有限公司 | 2025-06-13 | — | — | CN | disclosed |
| US-20250092057-A1 | HETEROCYCLIC RIP1 INHIBITORY COMPOUNDS | RIGEL PHARMACEUTICALS, INC. | 2025-03-20 | — | — | US | disclosed |
| CN-115298184-B | Heterocyclic RIP1 inhibiting compounds | 里格尔药品股份有限公司 | 2025-01-28 | — | — | CN | disclosed |
| CN-118724885-A | Benzoxazepine-diacid ester molecular hybridization derivative for inhibiting programmed cell necrosis and application thereof | 中国人民解放军海军军医大学 | 2024-10-01 | — | — | CN | disclosed |
| US-20240217958-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. | 2024-07-04 | — | — | US | disclosed |
| US-11919890-B2 | RIP1 inhibitory compounds and methods for making and using the same | ;Eli Lilly and Company (US) | 2024-03-05 | — | — | US | disclosed |
| CN-117624152-A | Biaryl benzoxazepine derivative and application thereof | 中国人民解放军海军军医大学 | 2024-03-01 | — | — | CN | disclosed |
| US-11718612-B2 | Inhibitors of receptor interacting protein kinase I for the treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718612-B2 | Inhibitors of receptor interacting protein kinase I for the treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-08-08 | — | — | US | disclosed |
| WO-2021046515-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-03-11 | — | — | WO | disclosed |
| EP-3788045-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | Rigel Pharmaceuticals, Inc. (US) | 2021-03-10 | — | — | EP | disclosed |
| CN-112384510-A | RIP1 inhibiting compounds and methods of making and using the same | 里格尔药品股份有限公司 | 2021-02-19 | — | — | CN | disclosed |
| US-20190337934-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | MIDCAP FINANCIAL TRUST | 2019-11-07 | — | — | US | disclosed |
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | AGOURON PHARMACEUTICALS, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | AGOURON PHARMACEUTICALS, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | AGOURON PHARMACEUTICALS, INC. | 2010-10-07 | — | — | US | disclosed |
| EP-2051966-A2 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | Pfizer Products Inc. (US) | 2009-04-29 | — | — | EP | disclosed |
| WO-2008017932-A2 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | PFIZER PRODUCTS INC. (US) | 2008-02-14 | — | — | WO | disclosed |
| WO-2008017932-A2 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | PFIZER PRODUCTS INC. (US) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11919890-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIPK1, RIPK2, RIPK3 | SMN1; SMN2 1818/4885KLKB1 2917/4885SLC26A6 4615/4885 |
| US-11718612-B2 | Inhibitors of receptor interacting protein kinase I for the treatment of disease | RIPK1, RIPK2, RIPK4 | SMN1; SMN2 998/4885KLKB1 3311/4885SLC26A6 4134/4885 |
| US-20240217958-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIPK1, RIPK2, RIPK3 | SMN1; SMN2 1818/4885KLKB1 2917/4885SLC26A6 4615/4885 |
| US-20250092057-A1 | HETEROCYCLIC RIP1 INHIBITORY COMPOUNDS | RIPK1, RIPK2, RIPK3 | SMN1; SMN2 2209/4885KLKB1 3683/4885SLC26A6 4593/4885 |
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | CA2, CA7, CA9 | SMN1; SMN2 4201/4885KLKB1 3563/4885SLC26A6 2038/4885 |
| US-20190337934-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIPK1, RIPK2, RIPK3 | SMN1; SMN2 1818/4885KLKB1 2917/4885SLC26A6 4615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.